20 results
8-K
EX-10.1
NMTRQ
9 Meters Biopharma, Inc.
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
other applicable anti-bribery or anti-corruption laws (individually and collectively, “Anti-Corruption Laws”), nor, to the Company’s knowledge, has … constitute a violation of Anti-Corruption Laws.
(p) Sarbanes-Oxley Act. The Company and each of its Subsidiaries is in material compliance with any
8-K
EX-2.1
5nbnw5
4 May 20
Completes concurrent financing of ~$22 million led by Orbimed Advisors, LLC
5:24pm
SC TO-I/A
EX-99
r7xnd2hb
28 Feb 20
Issuer tender offer statement (amended)
5:23pm
8-K
EX-2.1
4e1be
7 Oct 19
Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases
6:59am
424B5
tzbo 2fe0t
18 Mar 19
Prospectus supplement for primary offering
9:08am
424B5
nk8q3la
26 Oct 18
Prospectus supplement for primary offering
9:22pm
- Prev
- 1
- Next